The purpose of this literature review was to identify and describe the cost of obesity, the contributing factors, and the use of taxation as a possible method of control of this epidemic in a Canadian setting. A review of the current literature found on the PubMed/MEDLINE services of the National Institutes of Health as well as an analysis of Web content was conducted. The PubMed/MEDLINE search identified 677 articles pertaining to Canada and obesity, 323 articles relating to price policy, 26 articles concerning obesity and taxes, and 29 articles about obesity, Canada, and cost (1964-March 2007). The cost of obesity in Canada has been estimated at $4.3 billion per year, although no yearly figures are available. The contributing factors of obesity in Canada are multivariate, ranging from dietary patterns and physical inactivity to the availability of high-calorie foods at a low cost and greater accessibility. No Canadian studies have been conducted on the use of taxes to curb obesity or evaluating food price elasticity. The available literature suggests that the use of taxes is a viable option to address the issue of obesity in Canada.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1559-4572.2008.00012.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Factors for Coronary Events After Robotic Hybrid Off-Pump Coronary Revascularization.
J Cardiovasc Dev Dis
January 2025
Department of Cardiac Surgery, Lankenau Heart Institute, Main Line Health, Wynnewood, PA 19096, USA.
Objectives: The impact of long-term complications after robotic hybrid coronary revascularization (HCR), including persistent angina, repeat revascularization, and myocardial infarction (MI), remains limited. This study aims to determine the risk factors for coronary events after robotic HCR and their time-varying effects on outcomes.
Methods: We identified all consecutive patients who underwent robotic HCR at our institution.
Guidelines for the Management of Complications of Diabetes in Saudi Arabia Using Delphi Technique for Consensus Among National Experts.
Clin Pract
December 2024
Saudi National Diabetes Center, Saudi Health Council, Riyadh 13315, Saudi Arabia.
(1) Background: Saudi Arabia has one of the leading cases of diabetes globally, with approximately 27.8% of adults suffering from the disease. Given the negative consequences of diabetes mellitus (DM), it is critical to develop guidelines for its management.
View Article and Find Full Text PDFGlucose Lowering through Weight management (GLoW): a randomised controlled trial of the clinical and cost effectiveness of a diabetes education and behavioural weight management programme vs a diabetes education programme in adults with a recent diagnosis of type 2 diabetes.
Diabetologia
January 2025
MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Aims/hypothesis: UK standard care for type 2 diabetes is structured diabetes education, with no effects on HbA, small, short-term effects on weight and low uptake. We evaluated whether remotely delivered tailored diabetes education combined with commercial behavioural weight management is cost-effective compared with current standard care in helping people with type 2 diabetes to lower their blood glucose, lose weight, achieve remission and improve cardiovascular risk factors.
Methods: We conducted a pragmatic, randomised, parallel two-group trial.
Cushing syndrome.
Nat Rev Dis Primers
January 2025
Endocrine Division, Department of Medicine, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Québec, Canada.
Cushing syndrome (CS) is a constellation of signs and symptoms caused by excessive exposure to exogenous or endogenous glucocorticoid hormones. Endogenous CS is caused by increased cortisol production by one or both adrenal glands (adrenal CS) or by elevated adrenocorticotropic hormone (ACTH) secretion from a pituitary tumour (Cushing disease (CD)) or non-pituitary tumour (ectopic ACTH secretion), which stimulates excessive cortisol production. CS is associated with severe multisystem morbidity, including impaired cardiovascular and metabolic function, infections and neuropsychiatric disorders, which notably reduce quality of life.
View Article and Find Full Text PDFSemaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
Lancet Diabetes Endocrinol
January 2025
Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. Electronic address:
Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF and type 2 diabetes, subcutaneous once weekly semaglutide 2·4 mg conferred improvements in heart failure-related symptoms and physical limitations, bodyweight, and other heart failure outcomes. We aimed to determine whether these effects of semaglutide differ according to baseline HbA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!